Although GLP-1 receptor agonists (GLP-1RAs) have significantly advanced obesity treatment, their limitations underscore the need for new therapies that promote weight loss while preserving muscle and supporting metabolic health. Researchers from Rivus Pharmaceuticals Inc. discussed the discovery and preclinical profile of RV-8451, a potentially first-in-class, oral, nonpeptide GLP-1RA.
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric proteins are usually involved in its pathogenesis, the role of the dystrophin complex is not well studied in AMC. Utrophin, encoded by the UTRN gene, is an important fetal dystrophin homologue and was the focus of a recently presented study.
Clinical responses to BCMA- or GPRC5D-directed T-cell engagers in relapsed/refractory multiple myeloma (MM) are often limited by disease relapse and antigen escape, underscoring the need for dual-targeting strategies that enhance durability while mitigating cytokine-driven toxicity.
The advent of antibody-drug conjugates (ADCs) changed targeted cancer therapy by enabling the delivery of cytotoxic agents to cancer cells. Topoisomerase I inhibitors are commonly used as payloads in TROP2-directed ADCs, but they are linked to toxicity and emerging resistance. Degrader-antibody conjugates (DACs) go beyond conventional cytotoxic payloads by combining antigen targeting and selective protein degradation.
At the recently concluded congress of the European Hematology Association, researchers at Cogent Biosciences Inc. presented preclinical data on CGT-1145, a JAK2 V617F-mutant-selective inhibitor designed to preferentially target the mutant kinase while sparing wild-type JAK2.
IBI-3032 is a nonpeptide GLP-1 receptor agonist under development at Innovent Biologics Co. Ltd. for the potential treatment of obesity and other metabolic diseases. The company recently reported results of preclinical studies in which pharmacokinetic profiling was performed in vivo in different species, and the candidate’s in vivo efficacy was tested in a murine model with diet-induced obesity.
Integrin alpha-5 (ITGA5) is a central modulator of extracellular matrix signaling and has been tied to fibrosis and tissue damage, contributing to lupus nephritis (LN) pathogenesis. A group of researchers aimed to investigate the association between ITGA5 and LN and its inhibition as a potential strategy to improve renal outcomes.
Researchers from Innovent Biologics (Suzhou) Co. Ltd. presented preclinical efficacy data on IBI-3040, a dual agonist of amylin and calcitonin receptors (CTR). In vitro studies in UM-UC-3 cells expressing human CTR and amylin receptor subtypes AMY-1 and AMY-3 showed that IBI-3040 elicited robust receptor activation, as evidenced by cAMP accumulation assays.
Clinical evidence supports the integration of dual amylin and calcitonin receptor agonism (DACRA) with GLP-1, GIP and glucagon receptor signaling (triple G) as a synergistic approach for appetite modulation, insulin sensitivity and weight loss. Oban Biopharma Inc. is developing OBT-676, an oral small molecule that delivers full DACRA activity with triple G partial agonism for the treatment of metabolic disorders.
INHBE encodes the hepatokine activin E, a key mediator of liver-adipose crosstalk involved in the regulation of lipid metabolism and energy balance. Researchers from Innovent Biologics Co. Ltd. recently released preclinical efficacy data on IBI-3046, a novel RNAi therapeutic targeting INHBE.
RSS
